article thumbnail

AI in Pharmaceuticals: From Discovery to Market

Complex Discovery

Editor’s Note: Artificial intelligence (AI) is transforming the pharmaceutical industry, offering unprecedented opportunities to accelerate drug discovery, streamline clinical trials, and fortify intellectual property (IP) strategies.

article thumbnail

CAFC Orders Review of Extrinsic Evidence to Determine Proper Limit of Claimed pH Range

IP Watchdog

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Actelion Pharmaceuticals Ltd. Mylan Pharmaceuticals Inc. The Federal Circuit remanded the case for further consideration of extrinsic evidence from chemistry textbooks to determine the proper meaning of the claim term “a pH of 13 or higher.”

Evidence 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

USPTO-FDA Listening Session: Patient Advocates Want Access, Patent Advocates Want Evidence

IP Watchdog

Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) today jointly held an all-day listening session featuring speakers from patient advocacy and industry groups, academia, and brand and generic pharmaceutical companies who weighed in on the relationship between patents and affordable access to medicines.

Evidence 127
article thumbnail

SCOTUS Scraps Vanda’s Bid for Guidance on Obviousness Standard

IP Watchdog

Vanda Pharmaceuticals filed the petition following the U.S. The CAFC came to its decision in part because the court said the disclosure of clinical trials was evidence that a person of ordinary skill in the art “would have had a reasonable expectation of success.”

article thumbnail

What Recent Case Law Tells Us About the Importance of Consumer Surveys in Trademark Cases

IP Watchdog

District Court for the Southern District of Florida ruled against plaintiff Vital Pharmaceuticals, Inc.’s In each of these opinions, the court noted the absence of survey evidence (or, in the Vital Pharmaceuticals case, the inadequacy of an “almost comically flawed” survey). On August 3, 2021, the U.S. On June 7, 2021, the U.S.

Case Law 126
article thumbnail

Ninth Circuit Denies Review of Decision that IPR Proceedings Do Not Trigger FCA’s Public Disclosure Bar

IP Watchdog

The FCA claim was brought by patent attorney Zachary Silbersher against Valeant Pharmaceuticals, predecessor to Canadian drugmaker Bausch Health.

article thumbnail

Johnson & Johnson Reaches $700 Million Settlement Over Talcum Powder Litigation

Complex Discovery

This case highlights critical issues surrounding product safety, transparency, and the ethical responsibilities of corporations, especially within the pharmaceutical industry. The broader implications of this settlement will likely influence similar litigations and regulatory practices in the pharmaceutical and consumer goods industries.